Iron protects childhood acute lymphoblastic leukemia cells from methotrexate cytotoxicity

  title={Iron protects childhood acute lymphoblastic leukemia cells from methotrexate cytotoxicity},
  author={Marjan Abedi and Soheila Rahgozar and Abolghasem Esmaeili},
  journal={Cancer Medicine},
  pages={3537 - 3550}
Drug resistance is a fundamental clinical concern in pediatric acute lymphoblastic leukemia (pALL), and methotrexate (MTX) is an essential chemotherapy drug administered for the treatment. In the current study, the effect of iron in response to methotrexate and its underlying mechanisms were investigated in pALL cells. CCRF‐CEM and Nalm6 cell lines were selected as T and B‐ALL subtypes. Cells were pretreated with ferric ammonium citrate, exposed to the IC50 concentration of MTX and cell… Expand


Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia
It is proposed that iron availability modulates myeloid cell commitment and that targeting this cellular differentiation pathway together with conventional differentiating agents provides new therapeutic modalities for AML. Expand
Iron chelation: an adjuvant therapy to target metabolism, growth and survival of murine PTEN-deficient T lymphoma and human T lymphoblastic leukemia/lymphoma
The results demonstrate that targeting iron metabolism could be an interesting adjuvant therapy for acute lymphoblastic leukemia and displayed synergistic activity with three ALL-specific drugs: dexamethasone, doxorubicin, and L-asparaginase. Expand
Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells.
Oral CPX prevented the engraftment of primary AML cells in nonobese diabetic/severe combined immunodeficiency mouse models, thereby establishing its ability to target leukemia stem cells and has previously unrecognized anticancer activity at concentrations that are pharmacologically achievable. Expand
The relationship between iron bone marrow stores and response to treatment in pediatric acute lymphoblastic leukemia
Abstract Iron is an intracellular element whose accumulation in the body is associated with tissue damage. This study examines the effect of iron on pediatric acute lymphoblastic leukemia (ALL) andExpand
Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin.
It is shown that human MCF-7 breast cancer cells with an acquired resistance to the chemotherapeutic drugs doxorubicin and cisplatin exhibited substantial alterations in the intracellular iron content and levels of iron-regulatory proteins involved in the cellular uptake, storage and export of iron, especially in profoundly increased levels of ferritin light chain (FTL). Expand
Effects of Iron Deprivation on Multidrug Resistance of Leukemic K562 Cells
The results suggest a close relationship between iron deprivation and reduced MDR1/P-gp expression and function and suggest DFO may be used together with chemotherapeutic drugs to achieve better clinical efficacy. Expand
Iron Metabolism and Leukemia
Evidence of how iron metabolism and iron transporters influence the prognosis of leukemia is summarized and BDH2 predicts poor prognosis in CN-AML patients is demonstrated. Expand
Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia
The presence of Nrf2 signaling in human CLL is documented and altered NRF2 responses may contribute to the observed selective cytotoxicity of electrophilic compounds in this disease. Expand
A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics
Results indicate that the novel Fe chelators have potent and broad antitumor activity and can overcome resistance to established chemotherapeutics because of their unique mechanism of action. Expand
Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
This study indicates an antileukemic effect of DFX regardless of iron status and suggests that the use of D FX has a survival benefit for SIO leukemia murine model in terms of iron chelation and antileukesmic therapy. Expand